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Summary
Elevated catecholamines in the heart evoke transcriptional activation of the Myocyte Enhancer
Factor (MEF) pathway to induce a cellular response known as pathological myocardial
hypertrophy. We have discovered that the A-Kinase Anchoring Protein AKAP-Lbc is up-regulated
in hypertrophic cardiomyocytes. It coordinates activation and movement of signaling proteins that
initiate MEF2-mediated transcriptional reprogramming events. Live-cell imaging, fluorescent
kinase activity reporters and RNA interference techniques show that AKAP-Lbc couples
activation of protein kinase D (PKD) with the phosphorylation-dependent nuclear export of the
class II histone deacetylase HDAC5. These studies uncover a role for AKAP-Lbc in which
increased expression of the anchoring protein selectively amplifies a signaling pathway that drives
cardiac myocytes towards a pathophysiological outcome.
Introduction
Heart disease is a complex disorder that is a leading cause of death worldwide. Unfavorable
environmental factors and genetic profiles contribute to the etiology of several cardiac
disorders. These factors can adversely modify heart muscle contraction by interfering with
the fine-tuning of cardiomyocyte signal transduction cascades (Bassel-Duby and Olson,
2006). Activation of β-adrenergic receptors during periods of cardiac stress initially
improves cardiac output by increasing heart rate and contractility. However chronic
mobilization of the same signaling pathway ultimately harms the heart (Perrino and
Rockman, 2007). This is compounded by increased risk factors such as arterial hypertension
and valvular heart diseases that place additional biomechanical stress on the heart, inducing
a cellular response known as pathological cardiac hypertrophy. Hallmarks of this syndrome
include increased cardiomyocyte size and a greater organization of the sarcomere (Frey and
Olson, 2003). At the molecular level, hypertrophic signals, such as elevated adrenergic
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activity, evoke transcriptional activation of the Myocyte Enhancer Factor (MEF) (Bassel-
Duby and Olson, 2006). This induces a reprogramming of cardiac gene expression that
drives cardiomyocytes toward a development paradigm known as the “fetal gene response”
(Molkentin and Dorn, 2001).
A body of work suggests that signaling from the plasma membrane to the transcription
factor MEF2 is altered during pathological cardiac hypertrophy (Black and Olson, 1998).
MEF2 activity is controlled through its direct association with histone deacetylases
(HDACs). These enzymes deacetylate nucleosomal histones, thus promoting chromatin
condensation and transcriptional repression (Kouzarides, 2007). The class II histone
deacetylases (HDACs 4, 5, 7 & 9) are preferentially expressed in muscle cells (Grozinger
and Schreiber, 2000). Phosphorylation of these enzymes by calmodulin dependent (CaM)
kinases or the related protein kinase D releases them from association with MEF2 to permit
their export from nucleus (Backs et al., 2006; Bers and Guo, 2005; Sucharov et al., 2006;
Vega et al., 2004; Wu et al., 2006). The ensuing de-repression of MEF2 activity favors
transcription of cardiac genes that promote the fetal gene response causing a hypertrophic
phenotype (Chang et al., 2005). Although each component in this pathway is well defined,
much less is known about their integration into a dynamic cell-signaling cascade.
Cardiac A-Kinase Anchoring Proteins (AKAPs) play an active role in this process by
incorporating protein kinases, protein phosphatases, guanine nucleotide exchange factors
and phosphodiesterases (PDEs) into signaling complexes that respond to catecholamine
evoked changes in the production of second messengers (Chen et al., 2007; Dodge-Kafka et
al., 2005; Fink et al., 2001; Lygren et al., 2007). In cardiomyocytes AKAP-Lbc functions as
a scaffolding protein for PKA and PKC to mediate activation of a third enzyme, protein
kinase D (PKD1) (Carnegie et al., 2004). In this report we show that AKAP-Lbc is
upregulated in response to hypertrophic stimuli and functions to enhance the efficiency of
signaling through a PKD/HDAC5/MEF2 pathway that elicits the fetal gene response.
Results
AKAP-Lbc expression is elevated in hypertrophic NRVM
Initial experiments focused on establishing whether hypertrophic stimuli alter AKAP-Lbc
expression. Neonatal rat ventricular myocytes (NRVM) were exposed to the α1 adrenergic
agonist phenylephrine (PE, 10 μM) for 48 hours to evoke a cellular model of cardiac
hypertrophy (Clerk and Sugden, 1999). Quantitative RT-PCR showed that PE induced
AKAP-Lbc mRNA levels 1.7 ± 0.2 fold (n=4) over untreated cells (Fig 1A, top panel,
column 2). Data were normalized against the glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) gene. Comparable increases in AKAP-Lbc mRNA levels were measured in
NRVM treated with other hypertrophic agents such as endothelin (ET, 100 nM) [1.8 ± 0.2,
n=3] and isoproterenol (ISO, 10 μM) [1.8 ± 0.1, n=4] (Fig 1A, top panel, columns 3 & 4).
Control experiments confirmed that each agonist up-regulated two hypertrophic marker
genes, atrial natriuretic factor (ANF) and α-actinin (Fig 1A mid & bottom panels, columns
2–4).
Parallel studies monitored changes in AKAP-Lbc protein levels following PE treatment of
NRVM (Fig 1B). AKAP-Lbc was elevated 1.5 ± 0.2 fold (n=3) over untreated controls. (Fig
1B, top panel, lane 2). Increased expression of α-actinin indicated hypertrophy (Fig 1B, mid
panel, lane 2) and tubulin immunoblotting demonstrated equivalent protein loading (Fig 1B,
bottom panel). Cellular changes in AKAP-Lbc were further evaluated by
immunocytochemistry. Affinity purified antibodies were used to detect the anchoring
protein (green) in control NRVM (Fig 1C). Cells were also stained with the sarcomeric
marker α-actinin (red) and DAPI (blue) to denote the nucleus (Fig 1C, top panels). PE
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treatment increased cell size and enhanced the AKAP-Lbc staining concentrated in
perinuclear regions when compared to untreated NRVM (Fig 1C). Taken together these data
illustrate that AKAP-Lbc is elevated in hypertrophic cardiomyocytes. These results
substantiate gene array data showing that this anchoring protein (also called AKAP13) is
elevated in the hearts of mice with heart failure (van Oort et al., 2006).
Gene silencing of AKAP-Lbc in NRVM
RNA interference (RNAi) was used to test whether reduced expression of the anchoring
protein perturbed aspects of the hypertrophic response. Lentiviral vectors were used to
maximize the infection of NRVM with shRNA-GFP constructs (Appert-Collin et al., 2007).
Gene silencing was confirmed upon immunoblot analysis of AKAP-Lbc immune complexes
(Fig 2A, top panel, lane 2). Detection of tubulin was used as a loading control (Fig 2A,
bottom panel). Cells expressing the AKAP-Lbc shRNA constructs were identified by GFP
fluorescence (Fig 2B, top left panel). Immunostaining for α-actinin identified all NRVM
(Fig 2B, top right panel). A composite image is presented (Fig 2B, bottom left panel).
Phenylephrine effects were assessed by two independent methods: measuring changes in cell
size (Kodama et al., 2000), (Fig 2B, bottom right panel) and immunocytochemical detection
of ANF (Supplementary data S1). Following treatment with PE, the cells transfected with
control shRNA were 1.8 ± 0.2 fold larger (n=38) than NRVM expressing the rat AKAP-
Lbc-shRNA/GFP construct (Fig 2C, columns 2 & 3). Likewise, significant ANF expression
was induced by PE treatment of control shRNA cells, whereas induction of ANF was barely
detected in cells expressing the AKAP-Lbc shRNA construct (Supplementary data S1).
Thus, gene silencing of AKAP-Lbc blunts PE-induced hypertrophic responses in NRVM.
Additional support for this notion was provided by experiments that combined RNAi
silencing of the endogenous anchoring protein and rescue with human AKAP-Lbc forms
that are refractory to the rat-specific shRNA (Fig 2D–F). Rescue with full-length human
AKAP-Lbc ortholog induced a 1.9 ± 0.1 fold increase (n=48) in average cell size compared
to NRVM where the endogenous rat anchoring protein was knocked down (Fig 2D–F).
AKAP-Lbc is a chimeric molecule that functions as a kinase anchoring protein and a
guanine nucleotide exchange factor (GEF) for the small molecular weight GTPase Rho
(Diviani et al., 2001). Both enzyme classes have been implicated in the onset of cardiac
hypertrophy (Clerk and Sugden, 2000). Therefore, gene silencing/rescue experiments were
performed with modified AKAP-Lbc forms to delineate the contribution of each signaling
pathway in the PE response. When NRVM were rescued with the AKAP-Lbc Y2153F
mutant that lacks Rho GEF activity, we observed an agonist-induced increase in cell size
(1.7 ± 0.1 fold, n=54, Fig 2D–F) and elevated ANF levels (Supplementary data S2). A
smaller agonist-induced increase in cell size (1.2 ± 0.2 fold, n=40, Fig 2D–F) was observed
when NRVM were rescued with the AKAP-Lbc-ΔPKA mutant that cannot anchor PKA.
Thus anchoring of PKA may also contribute to this process. However a more significant
observation was that phenylephrine induced increases in NRVM size and ANF expression
were blocked when rescue experiments were performed with a truncated AKAP-Lbc form
(AKAP-Lbc 1-2339) that does not bind PKD1 (Fig 2D–F & Supplementary data S2 & S3).
These latter results imply that the PKD scaffolding function of AKAP-Lbc is the principle
factor in transduction of the hypertrophic response. Additional mapping experiments
identified multiple PKD1 binding sites in the c-terminal quarter of AKAP-Lbc
(Supplementary data S4).
AKAP-Lbc facilitates nuclear export of HDAC5
A variety of kinase signaling pathways induce cardiac gene reprogramming during
hypertrophy. A major pathway involves phosphorylation of class II HDACs (HDACs 4, 5, 7
& 9) by the calmodulin dependent kinases CaMKII or CaMKIV, or by PKD (McKinsey,
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2007). Phosphorylation of HDACs promotes their nuclear export, resulting in de-repression
of MEF2 activity and concomitant activation of target genes to propagate the hypertrophic
response (Fig 3A). Recent investigations suggest that CaM kinases selectively target
HDAC4 whereas PKD1 preferentially regulates HDAC5 action (Backs et al., 2006; Wu et
al., 2006). Therefore we postulated that AKAP-Lbc may facilitate the activation of the
PKD1 isoform may enhance nuclear export of HDAC5.
Initial support for this model was provided by live-cell imaging experiments in Cos7 cells.
We monitored the movement of fluorescently tagged HDAC5 in response to phorbol ester
(PDBu, 50 nM), a pharmacological activator of PKD (Waldron and Rozengurt, 2003). NIH
Image-J software was used to measure the relative intensity of fluorescent signals in defined
regions of the nucleus and cytoplasm of each cell. Measurements were conducted at 5
minute intervals for the duration of the experiments (Fig 3B–D). There was no discernable
movement of HDAC5-red fluorescent protein (RFP) in control cells for up to 81.3 ± 7 min
(n=36) after the application of PDBu. Yet the mean time for HDAC5-RFP nuclear export in
the presence of AKAP-Lbc-GFP was 42 ± 5 min (n= 41 cells) after the application of PDBu
(Fig 3B–D and Supplementary Movies 3B). Control experiments were performed with the
AKAP-Lbc 1-2339-GFP fragment that is unable to interact with PKD1. The mean time for
HDAC5-RFP nuclear export was 67 ± 9 min (n= 32 cells) after the application of PDBu and
suggested that AKAP-Lbc influences PKD1 to enhance nuclear export of the histone
deacetylase (Fig 3D).
Further studies were performed to assess the contribution of the GEF domain in AKAP-Lbc
and CaM kinases in this process. The rate of HDAC5-RFP nuclear export either in the
presence of AKAP-Lbc Y2153F (Supplementary data S5) or in cells pretreated with the
CaM kinase inhibitor KN93 (Supplementary data S6) was similar to cells expressing AKAP-
Lbc-GFP. This suggests that AKAP-Lbc-mediated nuclear export of HDAC5 proceeds via a
mechanism that involves activation of PKD1 and that this can occur in a manner that is
independent of Rho activation and CaM Kinase activity.
Nuclear export of class II HDACs triggers a fetal gene response in cardiomyocytes through
stimulation of a MEF2 transcriptional activation pathway. Therefore we used a luciferase
reporter (provided by Dr. Eric Olson, University of Texas-Southwestern) to examine MEF2-
mediated transcription. Cos7 cells express low levels of AKAP-Lbc, PKD and the histone
deacetylase thereby providing an ideal model cell line to study the role of this pathway in
transcriptional activation using the MEF2 reporter. PDBu-dependent stimulation of MEF2
transcription was increased 4.9 ± 1.7 fold (n=4) in the presence of AKAP-Lbc and was
further enhanced to 6.9 ± 1.4 fold (n=4) upon overexpression of PKD with the anchoring
protein (Fig 3E). Controls did not detect any PDBu-dependent stimulation of transcriptional
activity driven by a β-galactosidase reporter. These findings strengthen our view that
AKAP-Lbc mediated activation of PKD can stimulate MEF2 transcription.
The remainder of our analyses were conducted in primary cultures of NRVM to probe the
spatiotemporal dynamics of this signaling pathway in a more appropriate cellular context.
Nuclear export of HDAC5-RFP was complete within 66 ± 6 min (n=12 cells) after
application of PDBu in control NRVM (Fig 4A; top panels & Fig 4B, column 1). In cells
expressing AKAP-Lbc-YFP a more rapid PDBu-dependent nuclear export of HDAC5-RFP
was observed. Movement of HDAC5 from the nucleus was complete within 33 ± 3 min (n=
21 cells) (Fig 4A & B and Supplementary Movies 4A).
Similar data was obtained upon stimulation with endothelin-1 (ET-1, 100 nM), a potent
vasoconstrictor that is implicated in the onset of myocardial inflammation and hypertrophy
(Sugden and Clerk, 2005; Teerlink, 2005). Endothelin-dependent movement of HDAC5-
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RFP took 53.3 ± 4 min (n=35 cells) in control cells, but was reduced to 34 ± 5 min (n= 21
cells) upon overexpression of the anchoring protein (Fig 4C & D and Supplementary Movies
4C). Finally, we measured the rate of ET-1 dependent HDAC5-RFP nuclear export in cells
in which the endogenous rat AKAP-Lbc expression was silenced by RNAi. AKAP-Lbc
shRNA and control shRNA cells were identified by the co-expression of GFP as a marker
(Fig 4E, first panels). Endothelin-dependent nuclear export of HDAC5-RFP was
significantly delayed upon depletion of the anchoring protein [75 ± 5 min, n=13] as
compared to shRNA controls [53 ± 8 min, n=14] (Fig. 4E & F and Supplementary Movies
4E). These data reinforce our contention that AKAP-Lbc contributes to the enhancement of
HDAC5 nuclear export in cardiomyocytes.
In situ analysis of PKD activity
Our working hypothesis is that AKAP-Lbc mediated activation of PKD potentiates the
hypertrophic response. Accordingly, overexpression of AKAP-Lbc enhanced activation of
the kinase as assessed by immunoblot using anti-phospho-PKD Ser 744/748 antibodies
when phenylephrine, endothelin or PDBu was used as the agonist (Fig 5A & Supplementary
data S7). The time course of these events was further evaluated using a genetically encoded
fluorescence based D-Kinase Activity Reporter (DKAR) (Kunkel et al., 2007). PKD
phosphorylation of a consensus substrate sequence (LSRQLTAAVSE) results in a decrease
in Fluorescence Resonance Energy Transfer (FRET) as measured by dynamic changes in the
YFP/CFP ratio (Fig. 5B).
A nuclear localization signal (PKKKRKVEDA) was engineered into the parent DKAR
construct. This allowed us to selectively monitor PKD activity in the nucleus where HDAC5
is a likely substrate. ET-1 was applied to NRVM at time zero and fluorescent images were
collected at 30 sec intervals for 90 minutes (Fig 5C–E). Increased PKD activity was scored
as a decrease in the YFP/CFP ratio in a defined area of the nucleus. Half-maximal responses
were reached within 44 ± 3 min (n=11) following application of ET-1 in NRVM expressing
nDKAR alone (Fig 5C upper panels, Fig 5D blue line & Fig 5E column 1). However, the
rate and magnitude of the DKAR response was increased in NRVM expressing AKAP-Lbc-
mCherry showing a half maximal activation within 25 ± 3 min (n=15, Fig 5C lower panels,
Fig 5D orange line & Fig 5E column 2). Control experiments confirmed that the nDKAR
FRET ratio was reversed upon application of Gö6976 (500 nM), the most selective,
commercially available PKD inhibitor (Fig 5D). Hence AKAP-Lbc acts as a catalyst to
favor PKD activation and apparently increases the pool of active enzyme in the nucleus.
Both factors drive NRVM toward the nuclear exclusion of HDAC5. Additional imaging
experiments confirmed that pre-treatment of NRVM with Gö6976 blocks agonist-induced
nuclear export of HDAC5-RFP when compared to controls (Fig 5F).
PKA and PKD catalyze the phosphorylation dependent recruitment of 14-3-3 and nuclear
export of HDAC5
A pair of consensus 14-3-3 binding sites have been identified that encompass serine residues
259 and 498 on HDAC5 (McKinsey et al., 2000). Sequence analysis of these regions
showed that serine 259 lies within the context of a PKD substrate motif whereas the amino
acid residues surrounding serine 498 form a PKA phosphorylation site. Radiolabelling of
HDAC5 with purified kinases and peptide array analysis was used to further define the
relevant phosphorylation sites on the histone deacetylase (Supplementary data S8). In vitro
binding studies confirmed that phosphorylation of HDAC5 by either PKA or PKD1
permitted the recruitment of 14-3-3 (Fig 6A, lanes 1–4). However, 14-3-3 still bound to an
HDAC5 S259/498A double mutant upon phosphorylation by PKD1 (Fig 6A, lanes 5–7).
This inferred that additional 14-3-3 binding sites must reside on HDAC5. Upon further
inspection another consensus 14-3-3 binding motif was identified that included a possible
Carnegie et al. Page 5
Mol Cell. Author manuscript; available in PMC 2011 September 9.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
PKD substrate site at serine 660 (Fig 6B). Cell based studies with a family of HDAC5 point
mutants confirmed this hypothesis (Fig 6C bottom panel, lane 8). PKD1 dependent
recruitment of 14-3-3 was abolished only when all three sites were inactivated by the
introduction of a non-phosphorylatable alanine residue (Fig 6C top panel, lane 8). This
differed from the PKA dependent recruitment of 14-3-3 that was lost in HDAC5 mutants
lacking Ser 498 (Fig 6C, bottom panels, lanes 3, 5, 7 & 8). These observations were
consistent with live-cell imaging experiments conducted with CFP tagged versions of the
HDAC5. Any HDAC5 point mutant that lacked either Ser 498 or Ser 660 was not exported
from the nucleus when compared to the wild-type control (Fig 6D and Supplementary
Movies 6D). In contrast mutation of serine 259 to alanine minimally reduced the rate of
HDAC nuclear export from 57 ± 3 min (n=41) to 68 ± 3 min (n=44) when compared to the
wild type control (Fig 6E, column 2). Thus serine residues 498 and 660 may represent the
principal phosphorylation sites on HDAC5 that are required for the 14-3-3 dependent
nuclear export. Furthermore, two AKAP-Lbc associated kinases PKA and PKD1 may
cooperate to promote movement of HDAC5 into the cytoplasm.
Discussion
We propose that AKAP-Lbc is a previously unrecognized factor that selectively directs
catecholamine signals to the transcriptional machinery to potentiate the hypertrophic
response. The anchoring protein is both up-regulated under pathophysiological conditions
and organizes a signaling pathway that contributes to the onset of myocardial hypertrophy.
Although most of our study was conducted in neonatal rat cardiac myocytes, further support
for this concept was provided by analysis of human heart tissue samples obtained post
mortem from two individuals exhibiting hypertrophic myopathy; a 46 year old male, with a
left ventricular ejection fraction (LVEF) of 42%, and a 62 year old female, LVEF 12%. A 2
± 0.5 fold increase in AKAP-Lbc mRNA was measured over normal age-matched patient
controls (Supplementary data S9). While induction of cardiomyopathy is a multifaceted
process, we contend that AKAP-Lbc mobilizes a subset of effectors to enhance progression
of this syndrome. Our data support a model where AKAP-Lbc facilitates activation of
protein kinase D, which in turn phosphorylates the histone deacetylase HDAC5 to promote
its nuclear export (Fig 7A & 7B). Finally, the concomitant reduction in nuclear histone
deacetylase activity favors MEF2 transcription and the onset of cardiac hypertrophy (Fig
7C).
In response to signals from α1-adrenergic and endothelin receptors AKAP-Lbc facilitates
activation of anchored kinases that mobilize the transcriptional machinery. Signals
downstream of the α1-AR can also stimulate the small molecular weight GTPase Rho during
hypertrophy (Maruyama et al., 2002). Additionally, several Rho effectors were identified in
a genetic screen for modulators of class II HDAC phosphorylation (Chang et al., 2005).
These included Rho-GEF1/p115-GEF, also known as “Lbc’s second cousin” (Lsc; mouse
ortholog) on the basis of its homology to the anchoring protein. Since AKAP-Lbc also
possesses intrinsic Rho guanine nucleotide exchange factor (GEF) activity (Diviani et al.,
2001) it was important to delineate whether hypertrophic agonists exert their effects through
activation of anchored kinases or via the stimulation of Rho. Two findings point toward
kinase scaffolding as the predominant mechanism. First, AKAP-Lbc RNAi/rescue
experiments showed that PKD binding is necessary for PE induced hypertrophy, while
disruption of the AKAP-Lbc GEF activity had minimal effect (as assessed by cell size or
induction of ANF; Fig 2E & F, Supplementary data S2). Second, live-cell imaging showed
that disruption of the GEF activity in AKAP-Lbc had no effect on the rate of agonist-
dependent HDAC5-RFP nuclear export when compared with the wild type anchoring
protein (Supplementary data S5).
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While activation of PKD appears to be the primary function of AKAP-Lbc, it should be
noted that the anchoring protein may independently contribute to Rho activation through a
Gα12 pathway. It has recently been reported that overexpression of dominant interfering
mutants of Gα12 reduced phenylephrine-induced changes in cardiomyocyte size (Appert-
Collin et al., 2007). Therefore AKAP-Lbc may provide a locus for crosstalk between the
PKD and Rho signaling pathways in a context dependent manner. In the immune system
Rho is required for PKD’s effects on pre-T cell differentiation at the membrane but is not
necessary for PKD activation in the cytoplasm of mature T cells (Mullin et al., 2006).
Indeed, AKAP-Lbc may function as a pleiotropic effector by integrating PKD and Rho
action in certain subcellular locations while segregating these signaling pathways in other
regions of the cell.
Live-cell imaging with FRET based kinase activity reporters and fluorescently tagged
proteins offer different perspectives on the same cellular process. This has enabled us to
correlate changes in nuclear PKD activity with HDAC nuclear export. We now have a
clearer picture of how individual steps in this hypertrophic signaling pathway are coupled.
Overexpression of AKAP-Lbc increases the rate and strength of PKD activation (Fig 5D)
and accelerates the nuclear export of HDAC5 (Fig 4A–D). On the contrary a reduction in
AKAP-Lbc expression (by shRNA) virtually abolishes the movement of the histone
deacetylase. Technical limitations precluded the use of DKAR in cells expressing the
AKAP-Lbc shRNA with a GFP marker. Regardless, these experiments provide some of the
most compelling evidence to date on how AKAPs organize discrete molecular events that
relay signals from one cellular compartment to another.
HDACs are primed for nuclear export upon the phosphorylation-dependent recruitment of
14-3-3 proteins (Grozinger and Schreiber, 2000; Kao et al., 2001; McKinsey et al., 2001).
Our data add to the understanding of this concept in two ways. First of all, we show that
PKA phosphorylation of serine 498 on HDAC5 facilitates 14-3-3 binding. Since PKA and
PKD are components of the AKAP-Lbc scaffold it would appear that HDAC5
phosphorylation may represent a point of convergence for the phospholipid and cAMP
signaling pathways. However, PKA phosphorylation alone is not sufficient to induce nuclear
export as treatment with isoproterenol to elevate intracellular cAMP has no effect on
HDAC5 translocation in NRVM (J.S & G.K.C personal communication).
Secondly, we have characterized an additional and physiologically relevant 14-3-3
interaction site at serine 660 of the histone deacetylase. This site acts in conjunction with the
previously recognised sites at serines 259 and 498. Phosphorylation of two of these sites is
required for nuclear export as mutation of either Serine 498 or Serine 660 blocks HDAC5
movement. In contrast, mutation of Ser 259 reduces 14-3-3 binding but has a negligible
effect on HDAC5 movement (Fig 6B & E). These observations tally with current models for
14-3-3 action where the dimeric protein sequentially binds a pair of phosphoserine motifs on
its binding partner to elicit a biological response (Yaffe, 2002). The initial binding event
occurs at a “gatekeeper site” which in the case of HDAC5 could be either Ser 498 or Ser
660. Taken together these findings further substantiate the view that PKD is the principle
HDAC5 kinase.
As the concept of kinase anchoring has gained acceptance an underlying question is how
AKAPs influence physiologically important phosphorylation events. One emerging theme is
that aberrant signaling through AKAP complexes contributes to certain heart diseases
(Diviani, 2007; McConnachie et al., 2006). For example, Yotiao anchors PKA and the
phosphatase PP1 with the KCNQ1 potassium channel subunit to shape the duration of
cardiac action potentials in response to β-adrenergic agonists (Chen et al., 2005; Marx et al.,
2002; Westphal et al., 1999). Inherited mutations in Yotiao or the KCNQ1 channel subunit
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have been linked to Long QT Syndrome, a rare genetic disease characterized by stress
induced cardiac arrhythmias and sudden death (Chen et al., 2007; Kass and Moss, 2003).
Likewise, the cardiac muscle-selective anchoring protein, mAKAP, assembles a cAMP
signaling module consisting of PKA, PDE4D3, and Epac-1 (Dodge et al., 2001). A larger
mAKAP-ryanodine receptor (RyR) complex controls excitation-contraction coupling at the
sarcoplasmic reticulum (Marx et al., 2001). Pathophysiological changes in the enzyme
composition of this mAKAP-RyR complex that alter the phosphorylation state of the
channel have been linked to the onset of certain forms exercise induced arrhythmias in mice
(Lehnart et al., 2005). We now implicate AKAP-Lbc as a co-factor that amplifies PKD
signaling to HDAC5 to initiate a hypertrophic phenotype. Myocardial hypertrophy is
extremely common, affecting 14–18% of the general adult population (Benjamin and Levy,
1999; World Health Organization). Therefore it will be important to explore the role of the
AKAP-Lbc/PKD/HDAC5 signaling pathway in whole animal models, to establish whether
AKAP-Lbc is a valid biomarker for hypertrophic cardiomyopathy and to determine which
genes are initiated upon up-regulation of the anchoring protein.
Experimental Procedures
All Western blotting, RII overlays, immunoprecipitations and phosphorylation experiments
were performed as described previously (Westphal et al., 1999).
Cell culture, immunocytochemistry and live cell imaging
Cos7 cells were cultured on glass coverslips. All transfections were carried out using
Effectene reagent (Qiagen, Valencia, CA). Neonatal rat cardiomyocytes were cultured as
described in (Pare et al, 2005). After 1 day in culture, cells were treated with vehicle or
agonist for a further 48hrs at 37°C, prior to lysis and evaluation of AKAP-Lbc expression by
Western blot or RT-PCR.
Preparation of primary NRVM and confocal microscopy experiments, NRVM were as
described in (Dodge-Kafka et al., 2005). Cells were fixed in 3.7% paraformaldehyde in PBS
followed by staining for α-actinin or ANF. Secondary antibodies used were from Jackson
Immunoresearch. To determine the effect of shRNA expression on cellular hypertrophy,
myocytes were co-transfected with rat AKAP-Lbc shRNA-GFP or control (human AKAP-
Lbc) shRNA plasmid and pEYFP (Clontech). For rescue experiments FLAG-human AKAP-
Lbc constructs were used. Anti-actinin was used to stain sarcomeric Z-disks to distinguish
myocytes from contaminating fibroblasts. Images were acquired using a BioRad MRC1024
confocal microscope.
For all live cell imaging experiments NRVM were cultured on glass coverslips coated with
1% gelatin (Sigma). For ectopic expression of protein, NRVM were electroporated using a
modified Amaxa Nucleofector protocol. After incubation at 37 °C for 18–48 h post
electroporation, cells were washed twice with Hank’s balanced salt solution, mounted in a
Ludin chamber (Life Imaging Services) and imaged using a Leica AS MDW workstation.
Images were acquired as described in (Dodge-Kafka et al., 2005). Cells were treated with
ET-1 (100 nM working concentration) for 60 mins prior to treatment with the PKC and PKD
inhibitor Go 6976 (500 nM) to validate that we were measuring changes in PKD activity
rather than other basophilic kinases. Nuclear phosphatase activity was inhibited by
pretreatment with calyculin A (10 nM). Additional experiments were performed using cells
that were pretreated with the CaMK inhibitor KN93 (5 μM working concentration for 30
mins) to ensure that nDKAR was not detecting CaMK activity in NRVM.
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Statistical analyses
All data are expressed as mean ± standard error of the mean. Differences in quantitative
variables were examined by one-way analysis of variance (ANOVA), or an unpaired two-
tailed t test. A P value < 0.05 was considered significant (*), a P value < 0.01 was
considered very significant (**) and a P value < 0.001 was considered extremely significant
(***). All analyses were performed using InStat.
Note: Experimental details for RT-PCR, expression constructs used, in vitro HDAC5
phosphorylation, 14-3-3 binding assays and MEF2-luciferase assays are included in the
Supplementary data.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. AKAP-Lbc expression is elevated in hypertrophic rat neonatal cardiomyocytes
A) RT-PCR analysis of gene expression from RNA prepared from rat neonatal
cardiomyocytes (NRVM) treated with hypertrophic agonists. Cells were treated with
agonists for 48hrs prior to lysis with TriZol and preparation of RNA. All gene expression
data was normalized to GAPDH gene expression; AKAP-Lbc (top panel); α-actinin (middle
panel) and ANF (bottom panel). Lane 1: no treatment. Lane 2: PE; phenylephrine (working
concentration: 10 μM). Lane 3: ET; endothelin-1 (working concentration: 100 nM). Lane 4:
ISO; isoproterenol (working concentration: 10 μM).
Data are expressed as mean ± SEM. Differences in quantitative variables were examined by
one-way analysis of variance (ANOVA). A P value < 0.05 was considered significant (*), a
P value < 0.01 was considered very significant (**) and a P value < 0.001 was considered
extremely significant (***). All analyses were performed using InStat.
B) Immunoblot detection of AKAP-Lbc (top), α-actinin (middle) and tubulin (bottom) in
control and PE-treated NRVM. Cells were treated with PE for 48 hrs prior to lysis.
Quantitation of the average amounts of AKAP-Lbc was performed over three independent
experiments. NIH Image J software was used to calculate the relative intensity of each
AKAP-Lbc signal normalized to a tubulin loading control.
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C) Immunocytochemical detection of AKAP-Lbc in control and PE treated NRVM. Cells
were treated with PE for 48hrs prior to fixation, permeabilization and immunostaining.
Immunodetection of AKAP-Lbc (green; left panels), immunostaining for the sarcomeric
marker protein α-actinin (red; middle panels) and composite images with the nuclear stain
DAPI (blue; right panels) are presented. Images were collected on a BioRad MRC 1024
confocal microscope using identical settings for control and hypertrophic NRVM.
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Figure 2. Effects of RNAi knockdown of AKAP-Lbc in NRVM
A) Immunoblot showing RNAi knockdown of AKAP-Lbc in NRVM. Endogenous AKAP-
Lbc was immunoprecipitated from NRVM lysates after 72hrs exposure to shRNA. Proteins
were separated by SDS-PAGE and detected by Western blot. AKAP-Lbc (top panel),
tubulin loading control (lower panel).
B) Detection of AKAP-Lbc shRNA/GFP and measurement of cell size in hypertrophic
NRVM. NRVM expressing AKAP-Lbc shRNA/GFP were detected by green fluorescence
(top left panel). NRVM were fixed and stained for α-actinin (red, top right panel) 72hrs after
transfection of shRNA and incubation with PE (for 48hrs). A composite image is presented
(bottom, left panel). The outlines for control NRVM (white) and cells infected with the
AKAP-Lbc shRNA-GFP (yellow) are indicated (bottom, right panel).
C) The cell size of untransfected NRVM, cells expressing AKAP-Lbc shRNA/GFP, or a
control shRNA was measured using NIH Image J software. NRVM were treated with PE for
48 hrs prior to analysis. The amalgamated data are presented (number of cells measured in
each group is indicated).
D) Schematic diagram of human AKAP-Lbc constructs used to rescue the anchoring protein
shRNA phenotype: hAKAP-Lbc, hAKAP-Lbc-Y2153F (a GEF-dead mutant), hAKAP-Lbc-
ΔPKA (a mutant unable to bind PKA) and AKAP-Lbc 1-2339 (a C-terminal truncation
mutant that is unable to bind PKD; Supplementary data S3).
E) Measurement of cell size in hypertrophic cells expressing AKAP-Lbc shRNA/GFP with
human AKAP-Lbc rescue constructs. NRVM were fixed and stained for α-actinin (red)
72hrs after transfection of shRNA and incubation with PE. NRVM expressing AKAP-Lbc
shRNA/GFP were detected by green fluorescence. Co-expression of rescue constructs was
verified by anti-FLAG immunostaining (Supplementary data S2c).
F) Measurement of cell size following PE treatment. Control NRVM (column 1), NRVM
expressing hAKAP-Lbc (column 2), hAKAP-Lbc-Y2153F (column 3), AKAP-Lbc 1-2339
(column 4) and AKAP-Lbc-ΔPKA (column 5).
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Figure 3. Imaging AKAP-Lbc mediated nuclear export of HDAC5 and regulation of
transcription in Cos7 cells
A) Schematic diagram depicting the regulation of MEF2 transcription in response to
hypertrophic agonists. We postulate that AKAP-Lbc plays a central role in this pathway,
facilitating activation of PKD, causing phosphorylation and subsequent nuclear export of
HDAC5, thereby leading to de-repression of MEF2 transcription and cardiac gene
reprogramming events.
B) Live-cell imaging techniques were used to monitor the cellular location of HDAC5 in
Cos7 cells treated with phorbol ester (PDBu). PDBu was applied to Cos7 cells at 0 mins and
images were collected at designated times (indicated in each frame). Representative images
from cells expressing HDAC5-RFP (red; top panels) and cells co-expressing HDAC5-RFP
with AKAP-Lbc-GFP (green; bottom panels).
C) Quantitation of the relative nuclear and cytoplasmic intensity of HDAC5-RFP signal
carried out using NIH Image J software.
D) Amalgamated data indicating the time of HDAC5 nuclear export in Cos7 cells following
application of PDBu. Data are expressed as mean ± SEM. Differences in quantitative
variables were examined by ANOVA using the software InStat.
E) Analysis of MEF2-regulated transcriptional activity in response to PDBu in Cos7 cells
co-expressing AKAP-Lbc (lane 2) and PKD + AKAP-Lbc (lane 3). A Western blot of
lysates shows even loading across samples (tubulin loading control), equal ectopic
expression of AKAP-Lbc in lanes 2 and 3 and PKD in lane 4.
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Figure 4. AKAP-Lbc mediated HDAC5 nuclear export in NRVM
A) Time course of HDAC5-RFP (red) nuclear export in response to PDBu (top panels) and
nuclear export of HDAC5-RFP when co-expressed with AKAP-Lbc-YFP (bottom panels).
PDBu was applied to cells at 0 mins. AKAP-Lbc-YFP and control cells were identified by
YFP fluorescence (first panels).
B) Amalgamated data indicating the time of HDAC5 nuclear export following application of
PDBu in NRVM expressing HDAC5-RFP and YFP (control cells, column 1) or co-
expressing HDAC5-RFP with AKAP-Lbc-YFP (column 2). Data are expressed as mean ±
SEM. Differences in quantitative variables were examined by ANOVA, or an unpaired two-
tailed t test. All analyses were performed using InStat.
C) Time course of HDAC5-RFP (red) nuclear export in NRVM in response to endothelin-1
(ET) (top panels) and nuclear export of HDAC5-RFP when co-expressed with AKAP-Lbc-
YFP (bottom panels). ET-1 was applied to cells at 0 mins.
D) Amalgamated data indicating the time of HDAC5 nuclear export following application of
ET-1 in NRVM expressing HDAC5-RFP and YFP (control cells, lane 1) or co-expressing
HDAC5-RFP with AKAP-Lbc-YFP (column 2). Data are expressed as mean ± SEM.
Differences in quantitative variables were examined by ANOVA, or an unpaired two-tailed t
test using Instat.
E) The time course of ET-1 nuclear export HDAC5-RFP (red) in NRVM co-transfected with
control shRNA (top panels) or NRVM co-transfected with AKAP-Lbc-shRNA (green;
bottom panels). ET-1 was applied to cells at 0 mins.
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F) Amalgamated data indicating the time of HDAC5 nuclear export following application of
ET-1 in NRVM expressing HDAC5-RFP and control shRNA (column 1) or co-expressing
HDAC5-RFP with AKAP-Lbc-shRNA (column 2). Data are expressed as mean ± SEM.
Differences in quantitative variables were examined by ANOVA, or an unpaired two-tailed t
test using Instat.
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Figure 5. In situ analysis of PKD activity
A) Activation of PKD by AKAP-Lbc. HEK293 cells expressing PKD alone or co-expressing
PKD with AKAP-Lbc were untreated or stimulated with PE, or ET-1 prior to lysis. Proteins
were separated by SDS-PAGE. PKD activation was assessed by immunoblot using anti-
phospho-Ser-744/748 PKD antibodies (top panel). Loading controls for total PKD (middle
panel) and AKAP-Lbc (bottom panel) are presented.
B) Diagram showing the mechanism of action for the nuclear D Kinase Activity Reporter
(nDKAR). A decrease in Fluorescence Resonance Energy Transfer (FRET) equates to an
increase in PKD activity.
C) Pseudo-color images following the time course changes in the nDKAR FRET ratio (YFP/
CFP) in NRVM upon stimulation with ET-1. The first panels are brightfield images of the
cells, showing the location of nDKAR. Top panels show a typical response of nDKAR after
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application of ET-1. The bottom panels show a typical response of nDKAR in NRVM co-
expressing AKAP-Lbc.
D) Amalgamated traces of nDKAR FRET ratio in response to ET-1 in NRVM expressing
nDKAR alone (blue line; n=11 cells) or co-expressing nDKAR and AKAP-Lbc (orange line;
n=15 cells). ET-1 was added at 0 mins. The selective inhibitor Go 6976 was added after 60
mins to block PKD activity.
E) The time of half-maximal nDKAR response was measured and averaged for cells
expressing nDKAR alone (column 1) or cells co-expressing nDKAR and AKAP-Lbc
(column 2). Data are expressed as mean ± SEM. Differences in quantitative variables were
examined by ANOVA, using the software InStat.
F) Top panels: time course showing nuclear export of HDAC5-RFP when co-expressed with
AKAP-Lbc-YFP in NRVM in response to endothelin-1 (ET). Bottom panels: nuclear export
of HDAC5-RFP when co-expressed with AKAP-Lbc-YFP in cells treated with the inhibitor
Go 6976 prior to ET-1 application (at 0 mins).
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Figure 6. Analysis of HDAC5 phosphorylation and induction of 14-3-3-binding
A) Phosphorylation of HDAC5 by PKA or PKD induces 14-3-3 binding. Epitope tagged-
HDAC5 (lanes 2–4) or an HDAC5-S259/498A double mutant (lanes 5–7) were
immunoprecipitated from HEK293 cells and incubated with cell lysates expressing
FLAG-14-3-3γ (top panel). 14-3-3 binding was assessed under conditions where HDAC5
was either de-phosphorylated by incubation with λ-phosphatase (lanes 2 & 5) or
phosphorylated by PKA (lanes 3 & 6) or PKD (lanes 4 & 7) in vitro.
B) Diagram of phosphorylation sites that regulate 14-3-3 binding on HDAC5. Consensus
14-3-3 binding sites are denoted. Kinase phosphorylation sites are indicated in red.
C) Mapping the essential 14-3-3 binding sites on HDAC5. A family of seven HDAC5
mutants where serines 259, 498 and 660 were systematically replaced with alanine were
screened for interaction with 14-3-3 in HEK293 cells. Experiments were performed using
PDBu to activate PKD (top group) or with forskolin/IBMX to activate PKA (bottom group).
The presence of 14-3-3 in HDAC5 immune complexes was assessed by immunoblot (top
panels). Loading controls for 14-3-3 (middle panels) and HDAC5 (bottom panels) are
presented.
D) Cellular analysis of 14-3-3 binding sites on HDAC5 nuclear export. The movement of
each HDAC5 14-3-3 binding mutant was analyzed in NRVM. Representative images of a
time course depicting ET-1-dependent response of HDAC-CFP (top panels) and the
HDAC5-CFP S259S, S498A, S660A triple mutant (bottom panels).
E) Graph of amalgamated data from experiments measuring the rate of nuclear export
(mins) of each HDAC5 mutant. Statistical significance and number of cells measured is
indicated above each column.
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Figure 7.
Model showing the role of AKAP-Lbc in the regulation of cardiac hypertrophy, through the
PKD-HDAC5-MEF2 signaling pathway.
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